Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 93 articles:
HTML format



Single Articles


    July 2020
  1. PANOUTSOPOULOU K, Avgeris M, Magkou P, Mavridis K, et al
    miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33182.
    PubMed     Abstract available


    June 2020
  2. HANSEN JM, Nagle CM, Ibiebele TI, Grant PT, et al
    A healthy lifestyle and survival among women with ovarian cancer.
    Int J Cancer. 2020 Jun 16. doi: 10.1002/ijc.33155.
    PubMed     Abstract available


    April 2020
  3. JIANG YT, Gong TT, Zhang JY, Li XQ, et al
    Infertility and ovarian cancer risk: evidence from nine prospective cohort studies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33012.
    PubMed     Abstract available


  4. JUNG M, Gao J, Cheung L, Bongers A, et al
    ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Int J Cancer. 2020 Apr 10. doi: 10.1002/ijc.33005.
    PubMed     Abstract available


  5. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    PubMed     Abstract available


    March 2020
  6. GONG Y, Yang J, Wang Y, Xue L, et al
    Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites.
    Int J Cancer. 2020 Mar 24. doi: 10.1002/ijc.32990.
    PubMed     Abstract available


  7. SINGH A, Gupta S, Badarukhiya JA, Sachan M, et al
    "Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer".
    Int J Cancer. 2020 Mar 19. doi: 10.1002/ijc.32984.
    PubMed     Abstract available


  8. ESSERS PBM, van der Heijden M, Vossen D, de Roest RH, et al
    Ovarian cancer derived copy number alterations signatures are prognostic in chemoradiotherapy treated head and neck squamous cell carcinoma.
    Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32962.
    PubMed     Abstract available


    February 2020
  9. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    PubMed     Abstract available


  10. BENVENUTO G, Todeschini P, Paracchini L, Calura E, et al
    Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    Int J Cancer. 2020 Feb 25. doi: 10.1002/ijc.32935.
    PubMed     Abstract available


  11. KOTSOPOULOS J, Narod SA
    Prophylactic salpingectomy for the prevention of ovarian cancer; who should we target?
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32916.
    PubMed     Abstract available


    January 2020
  12. HANNIBAL CG, Frederiksen K, Vang R, Kurman RJ, et al
    Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide-based study.
    Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864.
    PubMed     Abstract available


  13. YOSHIHARA M, Kajiyama H, Yokoi A, Sugiyama M, et al
    Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32854.
    PubMed     Abstract available


    December 2019
  14. RAMRAJ SK, Elayapillai SP, Pelikan RC, Zhao YD, et al
    Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32830.
    PubMed     Abstract available


  15. WOLF D, Fiegl H, Zeimet AG, Wieser V, et al
    High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
    Int J Cancer. 2019 Dec 4. doi: 10.1002/ijc.32818.
    PubMed     Abstract available


    November 2019
  16. WANG T, Townsend MK, Simmons V, Terry KL, et al
    Pre- and Post- Diagnosis Smoking and Survival Following Diagnosis with Ovarian Cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32773.
    PubMed     Abstract available


  17. SOKOLENKO AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, et al
    Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776.
    PubMed     Abstract available


    October 2019
  18. KRATZER TB, Weinstein SJ, Albanes D, Mondul AM, et al
    Vitamin D Binding Protein and Risk of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Int J Cancer. 2019 Oct 29. doi: 10.1002/ijc.32758.
    PubMed     Abstract available


  19. LEE YJ, Kim D, Shim JE, Bae SJ, et al
    Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32729.
    PubMed     Abstract available


  20. SIMIN J, Rulla MT, Callens S, Engstrand L, et al
    Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32706.
    PubMed     Abstract available


  21. QIU JJ, Lin XJ, Tang XY, Zheng TT, et al
    Long Noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32692.
    PubMed     Abstract available


    September 2019
  22. LINK T, Passek S, Wimberger P, Frank K, et al
    Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32676.
    PubMed     Abstract available


  23. LYU T, Jiang Y, Jia N, Che X, et al
    SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32673.
    PubMed     Abstract available


  24. YI T, Feng Y, Sundaram R, Tie Y, et al
    Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Int J Cancer. 2019;145:1209-1220.
    PubMed     Abstract available


    August 2019
  25. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
    Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
    PubMed     Abstract available


  26. RICE MS, Poole EM, Willett WC, Tworoger SS, et al
    Adult Dietary Fat Intake and Ovarian Cancer Risk.
    Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32635.
    PubMed     Abstract available


  27. RAY-COQUARD I, Cibula D, Mirza MR, Reuss A, et al
    Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
    Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32606.
    PubMed     Abstract available


    July 2019
  28. RAAB M, Kobayashi NF, Becker S, Kurunci-Csacsko E, et al
    Boosting the apoptotic response of high grade serous ovarian cancers with CCNE1-amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32559.
    PubMed     Abstract available


  29. ZHU Q, Zhang J, Chen Y, Hu Q, et al
    Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.
    PubMed     Abstract available


    June 2019
  30. GRUNDY A, Ho V, Abrahamowicz M, Parent ME, et al
    Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: a case-control study.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32513.
    PubMed     Abstract available


    May 2019
  31. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
    Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
    PubMed     Abstract available


    April 2019
  32. CABASAG CJ, Arnold M, Butler J, Inoue M, et al
    The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32322.
    PubMed     Abstract available


    March 2019
  33. NURMI A, Muranen TA, Pelttari LM, Kiiski JI, et al
    Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Int J Cancer. 2019 Mar 30. doi: 10.1002/ijc.32309.
    PubMed     Abstract available


  34. LI H, Zhang W, Niu C, Lin C, et al
    Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32293.
    PubMed     Abstract available


  35. BALLABIO S, Craparotta I, Paracchini L, Mannarino L, et al
    Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number variation in 3p26.2 and 8q24.3.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32288.
    PubMed     Abstract available


    February 2019

  36. Expression of Concern: "Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells" by Hua Yang, Lili He, Patricia Kruk, Santo V. Nicosia and Jin Q. Cheng.
    Int J Cancer. 2019 Feb 27. doi: 10.1002/ijc.32225.
    PubMed    


  37. HE Y, Gu Z, Zhu Q, Chen M, et al
    CA125 over-release behavior following a 75-gram oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32237.
    PubMed     Abstract available


    January 2019
  38. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
    Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
    PubMed     Abstract available


  39. TRABERT B, Michels KA, Anderson GL, Brinton LA, et al
    Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32157.
    PubMed     Abstract available


  40. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
    Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
    PubMed     Abstract available


    December 2018
  41. FORTNER RT, Poole EM, Wentzensen NA, Trabert B, et al
    Ovarian cancer risk factors by tumor aggressiveness: an analysis from the Ovarian Cancer Cohort Consortium.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32075.
    PubMed     Abstract available


    November 2018
  42. KIM S, Wang M, Tyrer JP, Jensen A, et al
    A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
    PubMed     Abstract available


  43. SCHUBERT S, van Luttikhuizen JL, Auber B, Schmidt G, et al
    The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31992.
    PubMed     Abstract available


    September 2018
  44. LIU Z, Zhang S, Hou F, Zhang C, et al
    Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31887.
    PubMed     Abstract available


  45. MONDAL S, Roy D, Sarkar Bhattacharya S, Jin L, et al
    Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
    Int J Cancer. 2018 Sep 18. doi: 10.1002/ijc.31868.
    PubMed     Abstract available


  46. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Abstract available


    August 2018
  47. ZHANG C, Wang X, Anaya Y, Parodi L, et al
    Distinct Molecular Pathways in Ovarian Endometrioid Adenocarcinoma with Concurrent Endometriosis.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31768.
    PubMed     Abstract available


  48. JIN C, Liu Z, Li Y, Bu H, et al
    PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31800.
    PubMed     Abstract available


  49. LU X, Li Y, Xia B, Bai Y, et al
    Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based non-targeted and targeted analyses.
    Int J Cancer. 2018 Aug 16. doi: 10.1002/ijc.31807.
    PubMed     Abstract available


    July 2018
  50. AKINWUNMI B, Vitonis AF, Titus L, Terry KL, et al
    Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31758.
    PubMed     Abstract available


  51. CHEN HJ, Huang RL, Liew PL, Su PH, et al
    GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31750.
    PubMed     Abstract available


  52. AUSTRIA T, Marion C, Yu V, Widschwendter M, et al
    Mechanism of cytokinesis failure in ovarian cystadenomas with defective brca1 and p53 pathways.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31659.
    PubMed     Abstract available


    June 2018
  53. KO KP, Kim SJ, Huzarski T, Gronwald J, et al
    The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
    Int J Cancer. 2018;142:2263-2272.
    PubMed     Abstract available


    May 2018
  54. BIZZARO F, Falcetta F, D'Agostini E, Decio A, et al
    Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31596.
    PubMed     Abstract available


  55. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.
    Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581.
    PubMed     Abstract available


  56. HUANG RL, Chen HJ, Chen LY, Chao TK, et al
    Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
    Int J Cancer. 2018 May 7. doi: 10.1002/ijc.31580.
    PubMed     Abstract available


    April 2018
  57. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31535.
    PubMed     Abstract available


  58. AGOSTINI A, Brunetti M, Davidson B, Trope CG, et al
    Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31418.
    PubMed     Abstract available


    March 2018
  59. PAPAEVANGELOU E, Almeida GS, Box C, deSouza NM, et al
    The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31392.
    PubMed     Abstract available


    February 2018
  60. KAAKS R, Fortner RT, Husing A, Barrdahl M, et al
    Tumor-associated auto-antibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31335.
    PubMed     Abstract available


  61. LIEW PL, Huang RL, Weng YC, Fang CL, et al
    Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31324.
    PubMed     Abstract available


    January 2018
  62. LOKKEGAARD ECL, Morch LS
    Tibolone and risk of gynecological hormone sensitive cancer.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31267.
    PubMed     Abstract available


    December 2017
  63. KHAIRALLAH AS, Genestie C, Auguste A, Leary A, et al
    Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31200.
    PubMed    


  64. REIMER D, Boesch M, Wolf D, Marth C, et al
    Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31186.
    PubMed     Abstract available


    November 2017
  65. FORTNER RT, Schock H, Le Cornet C, Husing A, et al
    Ovarian Cancer Early Detection by Circulating CA125 in the context of Anti-CA125 Autoantibody Levels: Results from the EPIC cohort.
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31164.
    PubMed     Abstract available


  66. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Abstract available


  67. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Abstract available


    October 2017
  68. FELIX AS, Brasky TM, Cohn DE, Mutch DG, et al
    Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
    Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31127.
    PubMed     Abstract available


  69. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
    Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
    PubMed     Abstract available


    September 2017
  70. GAITSKELL K, Green J, Pirie K, Barnes I, et al
    Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31063.
    PubMed     Abstract available


  71. RICE MS, Rist PM, Winter AC, Kurth T, et al
    Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31062.
    PubMed     Abstract available


  72. JUNG S, Allen N, Arslan AA, Baglietto L, et al
    Anti-Mullerian Hormone and risk of ovarian cancer in nine cohorts.
    Int J Cancer. 2017 Sep 18. doi: 10.1002/ijc.31058.
    PubMed     Abstract available


    August 2017
  73. BABIC A, Harris HR, Vitonis AF, Titus LJ, et al
    Menstrual pain and risk of epithelial ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Int J Cancer. 2017 Aug 22. doi: 10.1002/ijc.31010.
    PubMed     Abstract available


  74. WU YH, Huang YF, Chang TH, Chou CY, et al
    Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-kappaB-mediated IKKbeta expression.
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.30932.
    PubMed     Abstract available


  75. MORCH LS, Dehlendorff C, Baandrup L, Friis S, et al
    Use of antidepressants and risk of epithelial ovarian cancer.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30919.
    PubMed     Abstract available


    July 2017
  76. WU AH, Pearce CL, Lee A, Tseng C, et al
    Timing of births and oral contraceptive use influences ovarian cancer risk.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30910.
    PubMed     Abstract available


  77. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Abstract available


  78. KRITSCH D, Hoffmann F, Steinbach D, Jansen L, et al
    Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30860.
    PubMed     Abstract available


    June 2017
  79. BIXEL K, Saini U, Bid HK, Fowler J, et al
    Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Int J Cancer. 2017 Jun 24. doi: 10.1002/ijc.30847.
    PubMed     Abstract available


  80. JAREID M, Licaj I, Olsen KS, Lund E, et al
    Does an epidemiological comparison support a common cellular lineage for similar subtypes of postmenopausal uterine and ovarian carcinoma? The Norwegian Women and Cancer Study.
    Int J Cancer. 2017 Jun 8. doi: 10.1002/ijc.30826.
    PubMed     Abstract available


    April 2017
  81. VERDOODT F, Kjaer Hansen M, Kjaer SK, Pottegard A, et al
    Statin use and mortality among ovarian cancer patients: A population-based cohort study.
    Int J Cancer. 2017 Apr 15. doi: 10.1002/ijc.30738.
    PubMed     Abstract available


    March 2017
  82. STALBERG K, Kjolhede P, Bjurberg M, Borgfeldt C, et al
    Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study - On behalf of the Swedish gynecological cancer group (SweGCG).
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30707.
    PubMed     Abstract available


  83. COBURN SB, Bray F, Sherman ME, Trabert B, et al
    International patterns and trends in ovarian cancer incidence, overall and by histologic subtype.
    Int J Cancer. 2017 Mar 3. doi: 10.1002/ijc.30676.
    PubMed     Abstract available


    February 2017
  84. SHI T, Wang P, Xie C, Yin S, et al
    BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Int J Cancer. 2017 Feb 8. doi: 10.1002/ijc.30633.
    PubMed     Abstract available


    January 2017
  85. PRAESTEGAARD C, Jensen A, Jensen SM, Nielsen TS, et al
    Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 19 studies.
    Int J Cancer. 2017 Jan 7. doi: 10.1002/ijc.30600.
    PubMed     Abstract available


    December 2016
  86. TANG FH, Hsieh TH, Hsu CY, Lin HY, et al
    KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.
    Int J Cancer. 2016 Dec 29. doi: 10.1002/ijc.30591.
    PubMed     Abstract available


  87. GARCIA-SANZ P, Trivino JC, Mota A, Perez Lopez M, et al
    Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
    Int J Cancer. 2016 Dec 20. doi: 10.1002/ijc.30573.
    PubMed     Abstract available


  88. JONES NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, et al
    Distinct molecular landscapes between endometrioid and non-endometrioid uterine carcinomas.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30537.
    PubMed     Abstract available


    October 2016
  89. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Abstract available


  90. PERES LC, Bandera EV, Qin B, Guertin KA, et al
    Dietary Inflammatory Index and Risk of Epithelial Ovarian Cancer in African American Women.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30467.
    PubMed     Abstract available


    September 2016
  91. HARRIS HR, Titus LJ, Cramer DW, Terry KL, et al
    Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.
    Int J Cancer. 2016 Sep 26. doi: 10.1002/ijc.30441.
    PubMed     Abstract available


  92. KRAUS C, Hoyer J, Vasileiou G, Wunderle M, et al
    Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30428.
    PubMed     Abstract available


    August 2016
  93. MARSHALL AD, van Geldermalsen M, Otte NJ, Anderson L, et al
    LAT1 is a Putative Therapeutic Target in Endometrioid Endometrial Carcinoma.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30371.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: